Investigator-initiated randomized controlled trials in infectious diseases: better value for money for registration trials of new antimicrobials
Randomized controlled trials (RCTs) conducted by the industry are expensive, especially trials conducted for registration of new drugs for multidrug-resistant (MDR) bacteria. Lower-cost investigator-initiated trials have recently been successful in recruiting patients with severe infections caused b...
मुख्य लेखकों: | Paul, M, Harbarth, S, Huttner, A, Thwaites, GE, Theuretzbacher, U, Bonten, MJM, Leibovici, L |
---|---|
स्वरूप: | Journal article |
भाषा: | English |
प्रकाशित: |
Oxford University Press
2020
|
समान संसाधन
-
Critical analysis of antibacterial agents in clinical development
द्वारा: Theuretzbacher, U, और अन्य
प्रकाशित: (2020) -
Antimicrobial stewardship initiatives throughout Europe: proven value for money
द्वारा: Edwin J.M. Oberjé, और अन्य
प्रकाशित: (2017-03-01) -
Towards achieving better value for money
द्वारा: National Seminar on Value Management (1999)
प्रकाशित: (1999) -
Clinical trials registration
द्वारा: Norman H Tiffin, और अन्य
प्रकाशित: (2013-01-01) -
Registration of clinical trials
द्वारा: Reza Negarandeh*, और अन्य
प्रकाशित: (2018-07-01)